297 related articles for article (PubMed ID: 10556213)
21. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
[TBL] [Abstract][Full Text] [Related]
22. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
23. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
[TBL] [Abstract][Full Text] [Related]
24. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
[TBL] [Abstract][Full Text] [Related]
25. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
Murray RJ; Kurilla MG; Griffin HM; Brooks JM; Mackett M; Arrand JR; Rowe M; Burrows SR; Moss DJ; Kieff E
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2906-10. PubMed ID: 2158098
[TBL] [Abstract][Full Text] [Related]
26. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines.
Wang EC; Lehner PJ; Graham S; Borysiewicz LK
Eur J Immunol; 1994 Nov; 24(11):2903-9. PubMed ID: 7525311
[TBL] [Abstract][Full Text] [Related]
27. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.
Hanley PJ; Lam S; Shpall EJ; Bollard CM
J Vis Exp; 2012 May; (63):e3627. PubMed ID: 22588077
[TBL] [Abstract][Full Text] [Related]
28. HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells.
Lindsley MD; Torpey DJ; Rinaldo CR
J Immunol; 1986 Apr; 136(8):3045-51. PubMed ID: 2420881
[TBL] [Abstract][Full Text] [Related]
29. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.
Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M
Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851
[TBL] [Abstract][Full Text] [Related]
30. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.
Papanicolaou GA; Latouche JB; Tan C; Dupont J; Stiles J; Pamer EG; Sadelain M
Blood; 2003 Oct; 102(7):2498-505. PubMed ID: 12805061
[TBL] [Abstract][Full Text] [Related]
31. Rapid generation of CMV pp65-specific T cells for immunotherapy.
Bao L; Sun Q; Lucas KG
J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
[TBL] [Abstract][Full Text] [Related]
32. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
[TBL] [Abstract][Full Text] [Related]
33. The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele.
Provenzano M; Lim JB; Mocellin S; Monsurro V; Bettinotti M; Marincola FM; Stroncek DF
Transfusion; 2003 Nov; 43(11):1567-74. PubMed ID: 14617317
[TBL] [Abstract][Full Text] [Related]
34. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
Carmichael A; Jin X; Sissons P; Borysiewicz L
J Exp Med; 1993 Feb; 177(2):249-56. PubMed ID: 8093890
[TBL] [Abstract][Full Text] [Related]
36. Oligopeptide induction of a secondary cytotoxic T-cell response to Epstein-Barr virus in vitro.
Schmidt C; Burrows SR; Moss DJ; Sculley TB; Misko IS
Scand J Immunol; 1991 Apr; 33(4):411-20. PubMed ID: 1708166
[TBL] [Abstract][Full Text] [Related]
37. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
J Hematother Stem Cell Res; 2002 Aug; 11(4):669-74. PubMed ID: 12201955
[TBL] [Abstract][Full Text] [Related]
38. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
[TBL] [Abstract][Full Text] [Related]
39. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.
Misko IS; Sculley TB; Schmidt C; Moss DJ; Soszynski T; Burman K
Cell Immunol; 1991 Feb; 132(2):295-307. PubMed ID: 1846323
[TBL] [Abstract][Full Text] [Related]
40. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
